Bausch Health Companies Inc. (BHC) News

Bausch Health Companies Inc. (BHC): $8.53

0.17 (+2.03%)

POWR Rating

Component Grades













Filter BHC News Items

BHC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BHC News Highlights

  • BHC's 30 day story count now stands at 28.
  • Over the past 24 days, the trend for BHC's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • SKIN, AMD and EYE are the most mentioned tickers in articles about BHC.

Latest BHC News From Around the Web

Below are the latest news stories about Bausch Health Companies Inc that investors may wish to consider to help them evaluate BHC as an investment opportunity.

Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.

Yahoo | February 24, 2022

Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Sam Eldessouky, executive vice president and chief financial officer; William Woodfield, senior vice president and treasurer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the J.P. Morgan Global High Yield & Leveraged Finance Conference in Miami on March 1, 2022 at 9:15 a.m. ET.

Yahoo | February 24, 2022

Bausch Health Companies Inc. (BHC) CEO Joseph Papa on Q4 2021 Results - Earnings Call Transcript

Bausch Health Companies Inc. (BHC) Q4 2021 Results Conference Call February 23, 2022 08:00 AM ET Company Participants Arthur Shannon - SVP, Head of IR Joseph Papa - Chairman, CEO Sam Eldessouky - CFO Thomas Appio - President, Co-Head Bausch + Lomb/International Scott Hirsch - CEO, Solta Medical Conference Call...

SA Transcripts on Seeking Alpha | February 23, 2022

Bausch Health Swings to Profit in Q4

Bausch Health Companies (TSE: BHC) (NYSE: BHC) swung to a profit from a loss in the fourth quarter of 2021. The manufacturer of health care products is fully ready to launch Solta and Bausch + Lomb IPOs. Revenues & Earnings Revenues came in at $2.196 billion for the quarter ended December 31, up 1% from $2.213 billion in the prior-year quarter.   The company reported a GAAP net income of $69 million ($0.19 per share) in Q4 2021, compared to a net loss of $153 million (-$0.43 per share) in Q4 2020.

Stephanie Bedard-Chateauneuf on TipRanks | February 23, 2022

Bausch Health (BHC) Beats Q4 Earnings Estimates

Bausch (BHC) delivered earnings and revenue surprises of 17.59% and 0.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Bausch Health swings to a profit, while revenue and full-year outlook misses expectations

Shares of Bausch Health Companies Inc. rallied 2.3% in premarket trading Wednesday, after the health care products company swung to fourth-quarter net income, while revenue and the full-year outlook fell shy of expectations. The company swung to net income of $69 million, or 19 cents a share, from a loss of $153 million, or 43 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted net income slipped to $463 million from $478 million, but the company did not provide adjuste

Yahoo | February 23, 2022

Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance

Fourth-Quarter 2021 Financial Results

Yahoo | February 23, 2022

Bausch Health Can't Seem to Pass Its Chart Exam as Earnings Approach

BHC is due to report their latest earning's figures on Wednesday before the market opens. In this updated daily bar chart of BHC, below, we can see that prices have been on defense the past 12 months. BHC is trading below the declining 50-day moving average line as well as the declining 200-day line.

Yahoo | February 22, 2022

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Yahoo | February 22, 2022

OraPharma Launches OraFit™ Custom Clear Dental Aligner System

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its oral health care business, OraPharma, today announced the U.S. launch of the OraFit™ custom clear aligner system, which is indicated for correcting malocclusion, which is also known as crooked or misaligned permanent teeth. The new OraFit™ aligner system uses high-performance materials in a three-layer design that offers dental professionals and their patients the latest in clear aligner technology and addresses the increased

Yahoo | February 22, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5334 seconds.